Top

BMC Medical Research Methodology

Published in:

Open Access 01-12-2016 | Research Article

Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data

Authors: Wenjie Wang, Ming-Hui Chen, Sy Han Chiou, Hui-Chuan Lai, Xiaojing Wang, Jun Yan, Zhumin Zhang

Published in: BMC Medical Research Methodology | Issue 1/2016

Abstract

Background

Persistent Pseudomonas aeruginosa (PPA) infection promotes lung function deterioration in children with cystic fibrosis (CF). Although early CF diagnosis through newborn screening (NBS) has been shown to provide nutritional/growth benefit, it is unclear whether NBS lowers the risk of PPA infection and how the effect of NBS vary with age. Modeling the onset age of PPA infection is challenging because 1) the onset age of PPA infection is interval censored in patient registry data; and 2) some risk factors such as NBS may have time-varying effects.

Methods

This problem fits into the framework of a recently developed Bayesian dynamic Cox model for interval censored data, where each regression coefficient is allowed to be time-varying to an extent determined by the data.

Results

Application of the methodology to data from the CF Foundation Patient Registry revealed interesting findings. Compared with patients with meconium ileus or diagnosed through signs or symptoms, patients diagnosed through NBS had significantly lower risks of acquiring PPA infection between age 1 and 2 years, and the benefit in survival rate was found to last up to age 4 years. Two cohorts of five years apart were compared. Patients born in cohort 2003–2004 had significantly lower risks of the PPA infections at any age up to 4 years than those born in 1998–1999.

Conclusions

The study supports benefits of NBS on PPA infection in early childhood. In addition, our analyses demonstrate that patients in the more recent cohort had significantly lower risks of acquiring PPA infection up to age 4 years, which suggests improved CF treatment and care over time.

Available only for authorised users

Cystic Fibrosis Foundation. CF Foundation Patient Registry Annual Data Report. 2013. https://www.cff.org/About-Us/Reports-and-Financials/Annual-Reports-and-Financials/.

Aebi C, Bracher R, Liechti-Gallati S, Tschäppeler H, Rüdeberg A, Kraemer R. The age at onset of chronic pseudomonas aeruginosa colonization in cystic fibrosis-prognostic significance. Eur J Pediatr. 1995; 154:69–73.CrossRef

Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4):345.CrossRefPubMedPubMedCentral

Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Hoffman G, Laessig R, Rock MJ, Splaingard M. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: Enough is enough!J Pediatr. 2005; 147(3):30–6.CrossRef

Zhang Z, Lindstrom MJ, Farrell PM, Lai HJ, Wisconsin Cystic Fibrosis Neonatal Screening Group. Pubertal height growth and adult height in cystic fibrosis after newborn screening. Pediatrics. 2016;137(5).

Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168(8):918–51.CrossRefPubMed

Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol. 2007; 42(9):751–6.CrossRefPubMed

Pressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, Høiby N, Kollberg H, Tümmler B, Vavrova V. Chronic pseudomonas aeruginosa infection definition: EuroCareCF working group report. J Cyst Fibros. 2011; 10:75–8.CrossRef

Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003; 24:6–52. doi:10.1086/503485.CrossRef

10.

Finkelstein DM. A proportional hazards model for interval-censored failure time data. Biometrics. 1986; 42:845–54.CrossRefPubMed

11.

Satten GA. Rank-based inference in the proportional hazards model for interval censored data. Biometrika. 1996; 83:355–70.CrossRef

12.

Pan W. Extending the iterative convex minorant algorithm to the Cox model for interval-censored data. J Comput Graph Stat. 1999; 8:109–20.

13.

Yan J, Cheng Y, Fine JP, Lai HJ. Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients. Biometrics. 2010; 66(2):594–602.CrossRefPubMed

14.

Wang X, Chen MH, Yan J. Bayesian dynamic regression models for interval censored survival data with application to children dental health. Lifetime Data Anal. 2013; 19(3):297–316. doi:10.1007/s10985-013-9246-8.CrossRefPubMed

15.

Kooperberg C, Clarkson DB. Hazard regression with interval-censored data. Biometrics. 1997; 53(4):1485–94.CrossRefPubMed

16.

Sinha D, Chen MH, Ghosh SK. Bayesian analysis and model selection for interval-censored survival data. Biometrics. 1999; 55(2):585–90.CrossRefPubMed

17.

Cai T, Betensky RA. Hazard regression for interval-censored data with penalized spline. Biometrics. 2003; 59(3):570–9.CrossRefPubMed

18.

Kneib T. Mixed model-based inference in geoadditive hazard regression for interval-censored survival times. Comput Stat Data Anal. 2006; 51(2):777–92.CrossRef

19.

Sun J. The Statistical Analysis of Interval-censored Failure Time Data. New York: Springer; 2006.

20.

Wang X, Chen M-H, Wang W, Yan J. dynsurv: Dynamic Models for Survival Data. 2014. R package version 0.2-2 http://CRAN.R-project.org/package=dynsurv.

21.

Schechter MS, Fink AK, Homa K, Goss CH. The cystic fibrosis foundation patient registry as a tool for use in quality improvement. BMJ Qual Saf. 2014; 23(Suppl 1):9–14.CrossRef

22.

Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003; 2(1):29–34.CrossRefPubMed

23.

Lee TWR, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol. 2004; 37(2):104–10.CrossRefPubMed

24.

Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr. 2005; 147(3):37–41.CrossRef

25.

Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns WT, Splaingard M, Mischler EH. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med. 1997; 337(14):963–9.CrossRefPubMed

26.

Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. 2004; 159(6):537–46.CrossRefPubMed

27.

Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575–606. doi:10.1002/humu.10041.CrossRefPubMed

28.

Thibodeau PH, Richardson MJ, Wang W, Millen L, Watson J, Mendoza JL, Du K, Fischman S, Hanoch S, Lukacs LG, Kirk K, Thomas JP. The cystic fibrosis-causing mutation ΔF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem. 2010; 285(46):35825–35.CrossRefPubMedPubMedCentral

29.

Green PJ. Reversible jump Markov chain Monte Carlo computation and Bayesian model determination. Biometrika. 1995; 82:711–32.CrossRef

30.

Brooks SP, Giudici P. Convergence Assessment for Reversible Jump MCMC Simulations. Bayesian Statistics 6 – Proceedings of the Sixth Valencia International Meeting In: Bernardo J. M, Berger J. O, Dawid A. P, Smith A. F. M, editors. New York: Clarendon Press [Oxford University Press]: 1999. p. 733–742.

31.

Geisser S, Eddy WF. A predictive approach to model selection. J Am Stat Assoc. 1979; 74(365):153–60.CrossRef

32.

Farrell MH, Farrell PM. Newborn screening for cystic fibrosis: Ensuring more good than harm. J Pediatr. 2003; 143(6):707–12.CrossRefPubMed

33.

Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS. Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2004; 53(RR-13):1–36. Recomm. Rep. 15;53(RR-13), MMWR Centers for Disease Control and Prevention. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5313a1.htm.

34.

Wang SS, FitzSimmons SC, O’Leary LA, Rock MJ, Gwinn ML, Khoury MJ. Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: A registry-based longitudinal study. Pediatrics. 2001; 107(2):274–9.CrossRefPubMed

35.

Sims EJ, McCormick J, Mehta G, Mehta A. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr. 2005; 147(3):42–6.CrossRef

36.

Baussano I, Tardivo I, Bellezza-Fontana R, Forneris MP, Lezo A, Anfossi L, Castello M, Aleksandar V, Bignamini E. Neonatal screening for cystic fibrosis does not affect time to first infection with Pseudomonas Aeruginosa. Pediatrics. 2006; 118(3):888–95.CrossRefPubMed

37.

Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012; 11(5):446–53.CrossRefPubMedPubMedCentral

38.

Grosse SD. Showing value in newborn screening: Challenges in quantifying the effectiveness and cost-effectiveness of early detection of phenylketonuria and cystic fibrosis. Healthcare. 2015; 3:1133–57.CrossRefPubMedPubMedCentral

39.

Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet. 1992; 8(11):392–8.CrossRefPubMed

40.

Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993; 73(7):1251–4.CrossRefPubMed

Title: Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data
Authors: Wenjie Wang
Ming-Hui Chen
Sy Han Chiou
Hui-Chuan Lai
Xiaojing Wang
Jun Yan
Zhumin Zhang
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Medical Research Methodology / Issue 1/2016
Electronic ISSN: 1471-2288
DOI: https://doi.org/10.1186/s12874-016-0220-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

A P-value model for theoretical power analysis and its applications in multiple testing procedures

Defining the clinical pathway in cochrane diagnostic test accuracy reviews

A scoping review of indirect comparison methods and applications using individual patient data

The use of purposeful sampling in a qualitative evidence synthesis: A worked example on sexual adjustment to a cancer trajectory

An evaluation of computerized adaptive testing for general psychological distress: combining GHQ-12 and Affectometer-2 in an item bank for public mental health research

The quality and diagnostic value of open narratives in verbal autopsy: a mixed-methods analysis of partnered interviews from Malawi